4579.T) announced">
Pulse News Wire translates Japanese corporate disclosures filed with the Tokyo Stock Exchange's TDNet system into clear, structured English for institutional investors, hedge funds, and asset managers. Every article on this page is derived directly from an official TDNet filing — including earnings reports, M&A announcements, share buybacks, dividend declarations, and governance changes. Japanese corporate governance is governed by the Companies Act and the Financial Instruments and Exchange Act; timely translation of these disclosures provides a material information advantage for cross-border investors monitoring Tokyo-listed equities.
This corporate disclosure from was processed by Pulse News Wire on February 13, 2026. It represents a primary source document for Japanese Governance sector intelligence, translated directly from an official filing submitted to the Tokyo Stock Exchange TDNet system.
Source disclosure: February 13, 2026 RaQualia Pharma Inc. [4579.T] TOKYO, Feb 13 (Pulse News Wire) – RaQualia Pharma Inc. (4579.T) announced changes to its executive leadership effective February 13, 2026. * Key changes: * Representative Director: 代表者名 代表取締役 須 藤 正樹 * Executive Officer: 問合せ先 執行役員経営管理部門担当 志 水 幹憲 * Representative Director: 連結子会社の代表取締役の異動に関するお知らせ * Representative Director: 当社の連結子会社であるファイメクス株式会社は、下記のとおり代表取締役の異動を決定いたしました * Representative Director: 1. 代表取締役の異動内